Bayer and Kumquat initiate Phase I study with KRAS G12D inhibitor in patients with KRAS-mutated tumors

First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors

Biostar Pharma doses first patient in Phase II/III multiregional trials of utidelone capsule

Cellipont and CellVax expand partnership to advance manufacturing of immunotherapy for GI cancers

The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product

Mitsui Chemicals launches InnoCell cell Culture microplates with exceptional oxygen permeability

InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services

Merck’s Welireg receives European approval for two indications

WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union

Cipla receives final approval for the generic version of Somatuline Depot Injection

Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection

Krazati monotherapy shows significant survival benefit in KRAS G12C-mutated NSCLC Phase III Krystal -12 data

The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024

Zydus launches generic version of Olaparib ‘IBYRA’ in India

The drug will target specific genetic mutations prevalent in certain types of cancers

USFDA grants Orphan Drug Designation for iOnctura's first-in-class autotaxin cancer therapy

It is the first autotaxin inhibitor to be investigated in cancer patients

Venus Remedies gets marketing approval for gemcitabine and docetaxel in Serbia

With this, the company has secured 511 marketing approvals for its oncology products across 66 countries